Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per share

Loss per share	9 Months Ended
Sep. 30, 2020
Loss per share
Loss per share	Note 4 — Loss per share The dilutive effect of 91,263,299 and 90,072,300 stock options outstanding as of September 30, 2020 and 2019 respectively have been excluded from the diluted loss per share calculation for the three and nine months ended September 30, 2020 and 2019, because they would have an antidilutive effect on the loss per share for the period.

Loss per share

9 Months Ended

Sep. 30, 2020

Note 4 — Loss per share

The dilutive effect of 91,263,299 and 90,072,300 stock options outstanding as of September 30, 2020 and 2019 respectively have been excluded from the diluted loss per share calculation for the three and nine months ended September 30, 2020 and 2019, because they would have an antidilutive effect on the loss per share for the period.